Warning against excessive transparency, Novo Nordisk said the upcoming transparency bills could impact its growth potential in key markets.

On Wednesday, drugmaker Novo Nordisk warned that the new legislation being prepared in some states in the U.S. which are aimed at bringing about transparency in pricing mechanisms could potentially impact its business in key markets.

“If the transparency bills lead to a disclosure level that is too excessive, it becomes difficult to do business, for instance, if we have to publicly share what is in our contracts,” said Lars Fruergaard Jorgensen, Novo Nordisk’s CEO. “A couple of states like Nevada and California have pursued transparency bills where we have to disclose, basically, how we do business”.

Categories: Creativity, Entrepreneurship, HR & Organization, Regulations & Legal, Strategy

Tags: bill, business, California, contracts, drugmaker, legislation, Nevada, Novo Nordisk, share, transact, transparency, U.S. States